Literature DB >> 26614196

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

G Günther1, F van Leth2, N Altet3, M Dedicoat4, R Duarte5, G Gualano6, H Kunst7, I Muylle8, V Spinu9, S Tiberi10, P Viiklepp11, C Lange12.   

Abstract

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26614196     DOI： 10.5588/ijtld.15.0274

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  6 in total

1.  Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

Authors:  A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk
Journal:  J Infect       Date:  2017-10-20       Impact factor: 6.072

2.  What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Authors:  Jan Heyckendorf; Sönke Andres; Claudio U Köser; Ioana D Olaru; Thomas Schön; Erik Sturegård; Patrick Beckert; Viola Schleusener; Thomas A Kohl; Doris Hillemann; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Stefan Niemann; Christoph Lange; Matthias Merker
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.

Authors:  Sarah Sengstake; Indra L Bergval; Anja R Schuitema; Jessica L de Beer; Jody Phelan; Rina de Zwaan; Taane G Clark; Dick van Soolingen; Richard M Anthony
Journal:  BMC Infect Dis       Date:  2017-07-12       Impact factor: 3.090

4.  Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.

Authors:  Jeong Ha Mok; Bo Hyoung Kang; Taehoon Lee; Hyun Kyung Lee; Hang Jea Jang; Yu Ji Cho; Doosoo Jeon
Journal:  J Korean Med Sci       Date:  2017-04       Impact factor: 2.153

5.  Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study.

Authors:  Sokleaph Cheng; Mallorie Hide; Sok Heng Pheng; Alexandra Kerléguer; Gauthier Delvallez; Sophan Sam; Tan Eang Mao; Thi Van Anh Nguyen; Anne-Laure Bañuls
Journal:  Infect Drug Resist       Date:  2021-03-17       Impact factor: 4.003

6.  Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.

Authors:  Demelash Woldeyohannes; Tesfaye Assefa; Rameto Aman; Yohannes Tekalegn; Zeleke Hailemariam
Journal:  PLoS One       Date:  2019-10-30       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.